An observational study in Hepatitis C, Chronic, sponsored by Kaiser Permanente. Completed. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2019-08-07.
Sponsored by Kaiser Permanente · Observational
The investigators will assess whether patients with the Hepatitis C virus (HCV) who are prescribed direct-acting antiviral (DAA) medications experience higher rates of adverse events than patients with HCV who are untreated. The investigators hypothesize that patients receiving DAAs do not experience higher rates of adverse events compared to patients who have not received DAAs. The study population is adults between the ages of 18 and 88 with any indication of a diagnosis of HCV. An intervention group (those receiving a DAA) and comparison group (those who are not treated) will be created using medication dispensing data. Eligibility for the study will be determined from January 1, 2011 through December 31, 2017. Covariates will be collected from January 1, 2011 through December 31, 2017. Individual study sites may have access to historical data prior to 2011 that can be used as covariates or to identify individuals with HCV. The primary outcomes of interest include acute myocardial infarction, neurological outcomes (e.g. acute stroke, intracranial bleed), acute kidney failure, acute on chronic liver failure, hepatic decompensation, multiple organ dysfunction syndrome, cancer, bradyarrhythmia, and death. The secondary outcomes include decompensated cirrhosis, hospitalization, emergency department visit, and arrhythmia. Outcomes will be assessed from January 1, 2011 through December 31, 2017. The investigators will use two different analytic approaches to answer the question of interest: a Poisson regression model and marginal structural modeling (MSM). The simpler Poisson model is an extension of tabular rate of event analysis. The more complicated MSM model incorporates modeling of the treatment decision to more flexibly control for confounding by indication. For each outcome, the investigators will only record the first date an outcome occurs. Each outcome will be modeled separately.
The groups/cohorts will consist of all HCV patients from Kaiser Permanente Southern California region, Kaiser Permanente Northern California region, and the OneFlorida Clinical Research Consortium.
Exclusion Criteria:
The results will be examined for sensitivity to the following possible exclusion criteria:
Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
Drug: Direct Acting Antivirals
The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
Incidence of Acute Myocardial Infarction (AMI)
Inpatient encounter with an ICD-9 diagnosis code of 410.xx or ICD-10 diagnosis code of I21.xx.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Acute on Chronic Liver Failure
An acute change in MELD (model for end stage liver disease) score of 5 or more and the change is deemed to have persisted (defined as meeting one of the following criteria: MELD continues to be elevated 3 months later, liver transplant, death). The minimum value for the MELD is 6.43, but there is no maximum value. Higher scores mean a worse outcome.
Time frame: Labs and diagnoses collected from clinical encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Acute Kidney Failure (AKF)
Encounters with an ICD-9 diagnosis code of 584.xx or ICD-10 diagnosis code of N17.xx.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Multiple Organ Dysfunction Syndrome (MODS)
Inpatient encounters with ICD-9 diagnosis code of 995.92, 995.94, 785.52 or ICD-10 code of R65.11 or R65.2x.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Death
Date of death in one or more records. Death data comes from medical records, Social Security, or state databases.
Time frame: Death dates will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Ischemic Stroke
Inpatient encounters with ICD-9 diagnosis code of 433.xx, 434.xx or ICD-10 code of I63.xx, I65.xx.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Hemorrhagic Stroke
Inpatient encounters with ICD-9 diagnosis code of 430.xx-432.xx or ICD-10 code of I60.xx-I62.xx
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Decompensated Cirrhosis
A patient will be characterized as having decompensated cirrhosis from an encounter indicating jaundice (ICD-9 diagnosis code of 782.4 or ICD-10 code of R17), ascites (ICD-9 diagnosis code of 789.5, 789.51, 789.59 or ICD-10 diagnosis code of R18.0, R18.8, K71.51, K70.11, or K70.31), or varices (ICD-9 diagnosis code of 456.0, 456.20 or ICD-10 diagnosis code of I85.01 or I85.11, or a medication dispense of lactulose or rifaximin along with a diagnosis of cirrhosis.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Rate of Hospitalizations
An encounter in which the place of service is an inpatient hospitalization.
Time frame: Hospitalizations will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Rate of Emergency Department Visits
An encounter in which the place of service is an emergency department or urgent care center.
Time frame: ED visits will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Arrhythmia
Inpatient encounters with an ICD-9 diagnosis code of 427.1, 427.42, 427.5, 427.9 or an ICD-10 diagnosis code of I47.2, I49.01, I49.02, I46.9, I49.9.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Liver Cancer
Encounters with ICD-9 diagnosis code of 155.xx or ICD-10 code of C22.xx.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of Cancers Other Than Liver Cancer
Encounters with ICD-9 codes 140.xx through 208.xx, except 155.xx or ICD-10 coes C00-C97 except C22.xx.
Time frame: Patient diagnoses collected from encounters will be examined through study completion, or up to 180 days from the day the patient initiated a DAA.
Incidence of HBV Reactivation
We identified HBV reactivations in three different ways \[Di Bisceglie et al., 2015; Yanny et al., 2018\]: (1) patients who had a history of Hepatitis B core antibody (HBcAb) positive and were Hepatitis B surface antigen (HBsAg) negative at the time of initiating DAA therapy who became HBsAg positive within 180 days after receiving a DAA; (2) patients with undetectable levels of HBV DNA at the time of initiating DAA therapy who had a numerical result within 180 days after receiving a DAA; (3) patients with a numerical HBV DNA result at the time of initiating DAA therapy whose viral load increased by a factor of 10 within 180 days after receiving a DAA. For all methods of detecting a reactivation, we required that the reactivations be clinically significant: bilirubin at least 3, aspartate aminotransferase (AST) at least 400, or alanine aminotransferase (ALT) at least 500.
Time frame: Labs will be for up to 180 days following the initiation of a DAA.
| Milestone | Direct Acting Antivirals | Comparison |
|---|---|---|
| Started | 15524 | 18284 |
| Completed | 15193 | 10210 |
| Not completed | 331 | 8074 |
Inpatient encounter with an ICD-9 diagnosis code of 410.xx or ICD-10 diagnosis code of I21.xx.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Acute Myocardial Infarction (AMI) | 3.3 (2.0 to 4.7) | 5.2 (4.6 to 5.8) |
An acute change in MELD (model for end stage liver disease) score of 5 or more and the change is deemed to have persisted (defined as meeting one of the following criteria: MELD continues to be elevated 3 months later, liver transplant, death). The minimum value for the MELD is 6.43, but there is no maximum value. Higher scores mean a worse outcome.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Acute on Chronic Liver Failure | 16.5 (13.3 to 19.7) | 24.1 (22.8 to 25.5) |
Encounters with an ICD-9 diagnosis code of 584.xx or ICD-10 diagnosis code of N17.xx.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Acute Kidney Failure (AKF) | 24.2 (20.5 to 28.0) | 33.7 (32.2 to 35.2) |
Inpatient encounters with ICD-9 diagnosis code of 995.92, 995.94, 785.52 or ICD-10 code of R65.11 or R65.2x.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Multiple Organ Dysfunction Syndrome (MODS) | 9.7 (7.4 to 12.0) | 17.2 (16.2 to 18.3) |
Date of death in one or more records. Death data comes from medical records, Social Security, or state databases.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Death | 10.7 (8.3 to 13.1) | 33.7 (32.3 to 35.1) |
Inpatient encounters with ICD-9 diagnosis code of 433.xx, 434.xx or ICD-10 code of I63.xx, I65.xx.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Ischemic Stroke | 3.6 (2.2 to 5.1) | 5.8 (5.1 to 6.4) |
Inpatient encounters with ICD-9 diagnosis code of 430.xx-432.xx or ICD-10 code of I60.xx-I62.xx
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Hemorrhagic Stroke | 1.5 (0.6 to 2.3) | 3.1 (2.6 to 3.5) |
A patient will be characterized as having decompensated cirrhosis from an encounter indicating jaundice (ICD-9 diagnosis code of 782.4 or ICD-10 code of R17), ascites (ICD-9 diagnosis code of 789.5, 789.51, 789.59 or ICD-10 diagnosis code of R18.0, R18.8, K71.51, K70.11, or K70.31), or varices (ICD-9 diagnosis code of 456.0, 456.20 or ICD-10 diagnosis code of I85.01 or I85.11, or a medication dispense of lactulose or rifaximin along with a diagnosis of cirrhosis.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Decompensated Cirrhosis | 23.8 (20.0 to 27.7) | 38.6 (37.0 to 40.2) |
An encounter in which the place of service is an inpatient hospitalization.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Rate of Hospitalizations | 162.8 (157.9 to 167.7) | 325.0 (320.6 to 329.4) |
An encounter in which the place of service is an emergency department or urgent care center.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Rate of Emergency Department Visits | 551.2 (542.3 to 560.2) | 853.4 (846.2 to 860.5) |
Inpatient encounters with an ICD-9 diagnosis code of 427.1, 427.42, 427.5, 427.9 or an ICD-10 diagnosis code of I47.2, I49.01, I49.02, I46.9, I49.9.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Arrhythmia | 3.2 (1.8 to 4.5) | 4.7 (4.1 to 5.2) |
Encounters with ICD-9 diagnosis code of 155.xx or ICD-10 code of C22.xx.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Liver Cancer | 9.3 (7.0 to 11.5) | 14.9 (13.9 to 15.8) |
Encounters with ICD-9 codes 140.xx through 208.xx, except 155.xx or ICD-10 coes C00-C97 except C22.xx.
| Events per 1000 person years | Direct Acting Antivirals | Comparison |
|---|---|---|
| Incidence of Cancers Other Than Liver Cancer | 20.7 (17.1 to 24.3) | 26.4 (25.0 to 27.7) |
We identified HBV reactivations in three different ways \[Di Bisceglie et al., 2015; Yanny et al., 2018\]: (1) patients who had a history of Hepatitis B core antibody (HBcAb) positive and were Hepatitis B surface antigen (HBsAg) negative at the time of initiating DAA therapy who became HBsAg positive within 180 days after receiving a DAA; (2) patients with undetectable levels of HBV DNA at the time of initiating DAA therapy who had a numerical result within 180 days after receiving a DAA; (3) patients with a numerical HBV DNA result at the time of initiating DAA therapy whose viral load increased by a factor of 10 within 180 days after receiving a DAA. For all methods of detecting a reactivation, we required that the reactivations be clinically significant: bilirubin at least 3, aspartate aminotransferase (AST) at least 400, or alanine aminotransferase (ALT) at least 500.
| Participants | Direct Acting Antivirals |
|---|---|
| Incidence of HBV Reactivation | 1 |
Collected over This was a retrospective observational study, so any adverse event data would have been collected during contact with a medical provider.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Direct Acting Antivirals | 77/15,524 (0.5%) | 0/15,524 (0%) | 0/15,524 (0%) |
| Comparison | 2,186/18,284 (12%) | 0/18,284 (0%) | 0/18,284 (0%) |
There is no difference between the number of baseline participants and the numbers in participant flow.
| Age, Categorical(Participants) | Direct Acting Antivirals | Comparison | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 12349 | 14638 | 26987 |
| >=65 years | 3175 | 3646 | 6821 |
| Sex: Female, Male(Participants) | Direct Acting Antivirals | Comparison | Total |
|---|---|---|---|
| Female | 6092 | 6962 | 13054 |
| Male | 9432 | 11322 | 20754 |
| Race (NIH/OMB)(Participants) | Direct Acting Antivirals | Comparison | Total |
|---|---|---|---|
| American Indian or Alaska Native | 112 | 116 | 228 |
| Asian | 891 | 772 | 1663 |
| Native Hawaiian or Other Pacific Islander | 49 | 51 | 100 |
| Black or African American | 2699 | 3838 | 6537 |
| White | 8670 | 9892 | 18562 |
| More than one race | 700 | 720 | 1420 |
| Unknown or Not Reported | 2403 | 2895 | 5298 |
| Region of Enrollment(Participants) | Direct Acting Antivirals | Comparison | Total |
|---|---|---|---|
| United States | 15524 | 18284 | 33808 |
No study locations are listed for this record.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided — Current plan is to make a de-identified data set available to investigators under specified conditions.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kaiser Permanente